Remimazolam

CHEMBL4297526 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
439.3 g/mol
LogP
3.4
Phase
4

Remimazolam is an ultra-short-acting benzodiazepine sedative that enhances GABA-A receptor-mediated inhibitory neurotransmission to produce dose-dependent sedation and anxiolysis, and is rapidly hydrolyzed by tissue esterases to an inactive metabolite, providing predictable and titratable sedation with rapid recovery. It is approved for procedural sedation and induction and maintenance of general anesthesia.

分子量

439.3000 g/mol

LogP

3.40

TPSA

69.40 Ų

リピンスキーの五則

適合

治療領域

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21

InChI

InChI=1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,10-12,17H,7,9H2,1-2H3/t17-/m0/s1

Molecular Formula

C21H19BrN4O2

HBD / HBA

- / 5

回転可能結合数

5

重原子数

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Remimazolam is an ultra-short-acting benzodiazepine sedative that enhances GABA-A receptor-mediated inhibitory neurotransmission to produce dose-dependent sedation and anxiolysis, and is rapidly hydrolyzed by tissue esterases to an inactive metabolite, providing predictable and titratable sedation with rapid recovery. It is approved for procedural sedation and induction and maintenance of general anesthesia.

Yes, Remimazolam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297526. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9867812. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.